Chongqing Peg-Bio Biopharm Co., Ltd.

Since the year 2000, Peg-Bio’s R&D team has been focusing on the research and development of innovative biological products, mainly recombinant protein drugs and peptide drugs. Thanks to its 20+ years of experience, Peg-Bio now owns four core technology platforms with global intellectual property, and a strong pipeline based on these technology platforms. Till today, 2 drug candidates in Peg-Bio’s pipeline are at NDA stage, 3 in Phase III clinical trial, 3 in Phase I-II stage, 3 under GLP evaluation and 3 in pre-clinical research phase. In the meantime, Peg-Bio has licensed out over a dozen biologics to top-ranking pharmaceutical companies internationally.

Along with its innovative drug development, Peg-Bio has also gained deep understanding and rich experience in recombinant proteases which are used for insulin/peptide production. And its recombinant Peptide Intermediates stand for top quality as well. To accommodate the needs from international clients for high-quality Proteases & Peptide Intermediates, Peg-Bio has built 3 workshops (fermentation scales from 100L, 1,500L to 3,000L), with the latter 2 workshops being operated in according with GMP. The global sales of these proteases and intermediates are carried out by iMED Bioscience, Peg-Bio's wholly owned subsidiary.

In the meantime, Peg-Bio is a renowned CDMO service provider in the field of recombinant drugs. With its superb recombinant technology and production processes, Peg-Bio is highly welcomed by start-up biotech and large biopharma alike.